Jazz Pharmaceuticals presented full survival data for its lung cancer drug Zepzelca (lurbinectedin) in combination with Roche's Tecentriq (atezolizumab) at ASCO 2025, based on the Phase 3 IMforte trial results.12345
The combination therapy reduced the risk of death by 27% versus Tecentriq alone as first-line maintenance for extensive-stage small cell lung cancer (ES-SCLC).23
Median overall survival was 13.2 months for the Zepzelca + Tecentriq group, compared to 10.6 months for Tecentriq alone.3
The combination also resulted in a 46% lower risk of cancer progression or death, with progression-free survival of 5.4 months (combo) vs. 2.1 months (Tecentriq alone).3
The data are regarded as statistically significant and clinically meaningful, supporting the potential for Zepzelca to move from post-chemo to first-line ES-SCLC treatment.45
Jazz Pharmaceuticals has submitted an application to the FDA for full approval of Zepzelca in this new setting following the positive Phase 3 results.2
Sources:
1. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-showcases-transformative-data-asco-2025
2. https://endpts.com/asco25-jazz-outlines-full-survival-data-for-lung-cancer-drug-zepzelca/
3. https://www.fiercepharma.com/pharma/asco-roche-jazz-zepzelca-small-cell-lung-cancer-win-leaves-room-improvement
4. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-showcases-transformative-data-at-asco-2025-highlighting-advances-in-small-cell-lung-cancer-her2-gastroesophageal-cancer-and-diffuse-glioma-302436392.html
5. https://www.appliedclinicaltrialsonline.com/view/zepzelca-tecentriq-survival-extensive-stage-small-cell-lung-cancer